3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
5
Active not recruiting
3
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Colorectal Neoplasms
26
Pancreatic Neoplasms
12
Stomach Neoplasms
11
Colonic Neoplasms
9
Rectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Esophageal Neoplasms
7
Adenocarcinoma Of Esophagus
7
Burkitt Lymphoma
6
Neoplasms
5
Cholangiocarcinoma
5
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Gallbladder Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Urachal cancer
1
Unresectable Colorectal Cancer
1
Interventions
pembrolizumab
35
Cisplatin
12
Paclitaxel
9
lenvatinib
7
Carboplatin
6
belzutifan
5
Saline Solution
4
Pemetrexed
4
Oxaliplatin
4
Fluorouracil
4
Leucovorin
3
Etoposide
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Surgical Procedures, Operative
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Leucovorin
×
Clear all
NCT05239741
2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
100 enrolled
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled
NCT04949256
2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
864 enrolled